ReviewActa haematologica2020
Multiple Myeloma in the Time of COVID-19.
Review in Acta haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Adverse events associated with cyclophosphamide: A pharmacovigilance study using the FDA adverse event reporting system.PloS one · 2026Article
- Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.European journal of neurology · 2024Article
- In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.Blood cancer journal · 2023Article
- The potential link between Covid-19 and multiple myeloma: A new saga.Immunity, inflammation and disease · 2022Review
- Article
- Targeting CD38 in Neoplasms and Non-Cancer Diseases.Cancers · 2022Review
- Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period.Leukemia · 2022Article
- Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.Clinical lymphoma, myeloma & leukemia · 2022Article
- Treatment Approaches for Managing Patients with Hematological Malignancies in the Time of COVID-19 Pandemic.Turkish journal of medical sciences · 2021Review
- Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020.Chronic diseases and translational medicine · 2021Article
- New insights into genetic characteristics between multiple myeloma and COVID-19: An integrative bioinformatics analysis of gene expression omnibus microarray and the cancer genome atlas data.International journal of laboratory hematology · 2021Article
- Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2.Journal of biomolecular structure & dynamics · 2021Review
- Article
- The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.European journal of haematology · 2021Article
- From the Editor's Desk: Publishing in Times of a Pandemic.Acta haematologica · 2021Article
- Should we screen patients with hematologic malignancies for COVID-19?Hematological oncology · 2020Review
- Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.Annals of hematology · 2020Observational
- Potential 'significance' of monoclonal gammopathy of 'undetermined significance' during COVID-19 pandemic.Blood cells, molecules & diseases · 2020Article
- COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.Blood cancer discovery · 2020Article
- Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality.Blood cancer journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We provide our recommendations (not evidence based) for managing multiple myeloma patients during the pandemic of COVID-19. We do not recommend therapy for smoldering myeloma patients (standard or high risk). Screening for COVID-19 should be done in all patients before therapy. For standard-risk patients, we recommend the following: ixazomib, lenalidomide, and dexamethasone (IRd) (preferred), cyclophosphamide lenalidomide and dexamethasone (CRd), daratumumab lenalidomide and dexamethasone (DRd), lenalidomide, bortezomib, and dexamethasone (RVd), or cyclophosphamide, bortezomib, and dexamethasone (CyBorD). For high-risk patients we recommend carfilzomib, lenalidomide, and dexamethasone (KRd) (preferred) or RVd. Decreasing the dose of dexamethasone to 20 mg and giving bortezomib subcutaneously once a week is recommended. We recommend delaying autologous stem cell transplant (ASCT), unless the patient has high-risk disease that is not responding well, or if the patient has plasma cell leukemia (PCL). Testing for COVID-19 should be done before ASCT. If a patient achieves a very good partial response or better, doses and frequency of drug administration can be modified. After 10-12 cycles, lenalidomide maintenance is recommended for standard-risk patients and bortezomib or ixazomib are recommended for high-risk patients. Daratumumab-based regimens are recommended for relapsed patients. Routine ASCT is not recommended for relapse during the epidemic unless the patient has an aggressive relapse or secondary PCL. Patients on current maintenance should continue their therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.